RxDoctor Payments Data

Herbert Cooper, MD

Adult Reconstructive Orthopaedic Surgery · New York, NYNPI 1376798850

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.1%), speaking fees and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Zimmer Biomet at 49.3% of the total. Reporting peaked in 2022 at $337,361 and has fallen 50.4% since, to $167,437 in 2025. Among adult reconstructive orthopaedic surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,307,851in general payments, 2019–2025

Across 894 payments — averaging $1462.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$645K
  • KCI USA, Inc.$527K
  • Solventum Corporation$94K
  • Depuy Synthes Products, Inc.$18K
  • Polarisar Inc$11K
  • Johnson & Johnson$5K
  • plus $8K from 9 others
$174,984in research payments, 2019–2025

Across 15 payments — averaging $11,666 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$175K

What the payments were for

  • Consulting fees$616,52147%
  • Speaking & faculty fees$433,28433%
  • Travel & lodging$114,9729%
  • Food & beverage$16,4071%
  • Education$126,66710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,307,851 in reported general payments places this provider in the 90th percentile of 85 adult reconstructive orthopaedic surgery providers in New York.

See all adult reconstructive orthopaedic surgery providers in New York

Medicare billing

Part B allowed, 2024
$752,928
Medicare patients
905
Services billed
7,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin12$22,814
Celecoxib55$2,927
CeftriaxoneCeftriaxone Sodium11$677
Meloxicam110$304
Oxycodone Hcl41$172
Tramadol Hcl50$170
Methylprednisolone12$111

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →